









Markets
/
Stocks
/
nasdaq-lucd
/

Lucid Diagnostics Inc

LUCD

1.165USD

+0.045+4.02%

Market hours （ET）Quotes delayed by 15 min

43.10MMarket Cap

LossP/E TTM



Lucid Diagnostics Inc

1.165

+0.045+4.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lucid Diagnostics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Lucid Diagnostics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 94 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.19.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lucid Diagnostics Inc's Score

Industry at a Glance

Industry Ranking

94 / 208

Overall Ranking

225 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lucid Diagnostics Inc Highlights

StrengthsRisks

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 93.82% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.71M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.71M.

Undervalued

The company’s latest PE is -1.62, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.02M shares, increasing 26.67% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.97M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.950

Target Price

+243.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Lucid Diagnostics Inc is 6.34, ranking 156 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.50M, representing a year-over-year increase of 25.65%, while its net profit experienced a year-over-year increase of 40.94%.

Score

Industry at a Glance

Previous score

6.34

Change



Financials

8.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.65

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lucid Diagnostics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Lucid Diagnostics Inc is 8.31, ranking 29 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.62, which is -67.31% below the recent high of -0.53 and -17.60% above the recent low of -1.90.

Score

Industry at a Glance

Previous score

8.31

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Lucid Diagnostics Inc is 8.40, ranking 34 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 3.00, with a high of 8.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

3.950

Target Price

+243.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Lucid Diagnostics Inc

LUCD

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Lucid Diagnostics Inc is 6.46, ranking 124 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.38 and the support level at 0.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.26

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.070

Sell

RSI(14)

28.750

Sell

STOCH(KDJ)(9,3,3)

6.510

Oversold

ATR(14)

0.071

High Vlolatility

CCI(14)

-134.679

Sell

Williams %R

91.917

Oversold

TRIX(12,20)

-0.392

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.182

Sell

MA10

1.256

Sell

MA20

1.339

Sell

MA50

1.295

Sell

MA100

1.197

Sell

MA200

1.163

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Lucid Diagnostics Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 29.04%, representing a quarter-over-quarter increase of 79.18%. The largest institutional shareholder is The Vanguard, holding a total of 4.97M shares, representing 3.79% of shares outstanding, with 288.35% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

PAVmed Inc

38.82M

+24.01%

The Vanguard Group, Inc.

Star Investors

4.52M

+9.61%

Masters Capital Management, L.L.C.

4.00M

+46.64%

BlackRock Institutional Trust Company, N.A.

3.32M

+1.67%

Aklog (Lishan)

1.54M

+5.11%

abrdn Inc.

2.50M

Two Seas Capital LP

3.00M

Geode Capital Management, L.L.C.

1.67M

+6.14%

McGrath (Dennis M)

1.39M

+5.69%

O'Neil (Shaun)

876.76K

+6.05%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lucid Diagnostics Inc is 3.41, ranking 126 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.